Matthew J Rendo
Overview
Explore the profile of Matthew J Rendo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
52
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grossmann M, Kou C, Vergonet B, Soderstrom M, Rendo M, Lee L
Mil Med
. 2024 May;
189(7-8):e1835-e1838.
PMID: 38720563
Testicular malignancies commonly affect adolescent and young adult males. Although they tend to respond well to cisplatin-based chemotherapy with excellent overall survival, complications such as inferior vena cava tumor thrombus...
2.
Flanagan K, Earls J, Schillebeeckx I, Hiken J, Wellinghoff R, LaFranzo N, et al.
J Cancer Res Clin Oncol
. 2023 Aug;
149(15):14125-14136.
PMID: 37552307
Purpose: Anti-PD-1 therapy provides clinical benefit in 40-50% of patients with relapsed and/or metastatic head and neck squamous cell carcinoma (RM-HNSCC). Selection of anti- PD-1 therapy is typically based on...
3.
Rendo M, Joseph J, Phan L, DeStefano C
Blood Lymphat Cancer
. 2022 Sep;
12:119-136.
PMID: 36060553
The therapeutic landscape of multiple myeloma (MM) has benefited from an emergence of novel therapies over the last decade. By inducing T-cell kill of target cancer cells, chimeric antigen receptor...
4.
Christensen B, Rendo M, Beeler B, Huddleston B, Fenderson J
Cureus
. 2022 Apr;
14(3):e23398.
PMID: 35481321
Humoral hypercalcemia of malignancy (HHM) is a paraneoplastic syndrome caused by elevations in parathyroid hormone-related protein (PTH-rP). HHM often presents in patients with squamous cell carcinomas of the lung, head,...
5.
McCarthy P, Rendo M, Uy M, Adams A, OShea A, Nelson D, et al.
Onco Targets Ther
. 2021 Jun;
14:3537-3544.
PMID: 34103944
Pancreatic ductal adenocarcinoma (PDAC) remains deadly despite advances in systemic therapies and surgical techniques. While there is increasing utilization of immune therapies across diverse cancer types, PDAC remains generally resistant...
6.
Nair P, Rendo M, Reddoch-Cardenas K, Burris J, Meledeo M, Cap A
Semin Hematol
. 2020 Sep;
57(2):73-82.
PMID: 32892846
Hematologic diseases include a broad range of acquired and congenital disorders, many of which affect plasma proteins that control hemostasis and immune responses. Therapeutic interventions for these disorders include transfusion...
7.
Kay C, Rendo M, Gonzales P, Beganovic S, Czader M
Case Rep Oncol Med
. 2019 Oct;
2019:9781065.
PMID: 31583147
Hemophagocytic lymphohistiocytosis (HLH) is a rare, hyperinflammatory syndrome characterized by clinical signs and symptoms of extreme inflammation. In adults, HLH is typically a complication of infections, autoimmune diseases, and malignancies....
8.
Fenderson J, Meledeo M, Rendo M, Peltier G, McIntosh C, Davis K, et al.
Transfusion
. 2019 Apr;
59(S2):1560-1567.
PMID: 30980741
Background: Cryoprecipitate's shelf life is limited due to concerns over decreased clotting factor activity and contamination with extended storage. Hemostatic characteristics of thawed cryoprecipitate stored up to 35 days at...